重性抑郁障碍的激素治疗:现状综述
本文综述了重性抑郁障碍(MDD)激素治疗的现状,描述了下丘脑-垂体-肾上腺(HPA)轴、下丘脑-垂体-甲状腺(HPT)轴和下丘脑-垂体-性腺(HPG)轴的生理机制,并评估了基于这些轴的激素干预措施作为单药或辅助治疗的研究证据。部分干预措施在临床前向临床转化中基本失败,另一些则显示出有希望的初步结果,是寻找MDD新型有效治疗的活跃研究领域。
要点
- HPA轴干预包括促肾上腺皮质激素释放因子拮抗剂和糖皮质激素受体拮抗剂米非司酮。
- HPT轴干预为甲状腺激素(T3和T4),HPG轴干预包括雌激素替代治疗、孕酮衍生物别孕烷醇酮和睾酮。
- 部分激素治疗在临床前向临床转化中基本失败,另一些显示出有希望的初步结果。
核心结论
- 靶向特定激素系统是治疗重性抑郁障碍的有理论基础且已显示前景的方法。
- 部分激素干预未能从临床前研究转化,另一些显示出有希望的初步结果并构成活跃研究领域。
研究设计与样本
- 本文为综述,描述HPA、HPT和HPG轴的生理机制,并复习所选激素干预治疗抑郁的证据,为临床医生和研究者提供该领域最新进展。
主要发现
- 重性抑郁障碍常见且伴随显著痛苦、患病、死亡和成本负担,许多患者对传统抗抑郁药应答不充分。
- 激素的治疗作用不仅归因于外周内分泌系统调节,也归因于激素对非内分泌脑环路的CNS效应。
- 综述聚焦HPA轴的促肾上腺皮质激素释放因子拮抗剂与糖皮质激素受体拮抗剂米非司酮、HPT轴的甲状腺激素(T3和T4)、HPG轴的雌激素替代治疗、孕酮衍生物别孕烷醇酮和睾酮。
临床怎么用
- 综述旨在为临床医生和研究者提供重性抑郁障碍激素治疗领域的最新进展。
- 激素干预可作为单药或辅助治疗用于重性抑郁障碍的评估。
- 靶向激素系统是治疗重性抑郁障碍的有前景的概念性方法。
局限性
- 部分激素治疗在从临床前研究向临床转化中基本失败。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Major depressive disorder is a common psychiatric disorder associated with marked suffering, morbidity, mortality, and cost. The World Health Organization projects that by 2030, major depression will be the leading cause of disease burden worldwide. While numerous treatments for major depression exist, many patients do not respond adequately to traditional antidepressants. Thus, more effective treatments for major depression are needed, and targeting certain hormonal systems is a conceptually based approach that has shown promise in the treatment of this disorder. A number of hormones and hormone-manipulating compounds have been evaluated as monotherapies or adjunctive treatments for major depression, with therapeutic actions attributable not only to the modulation of endocrine systems in the periphery but also to the CNS effects of hormones on non-endocrine brain circuitry. The authors describe the physiology of the hypothalamic-pituitary-adrenal (HPA), hypothalamic-pituitary thyroid (HPT), and hypothalamic-pituitary-gonadal (HPG) axes and review the evidence for selected hormone-based interventions for the treatment of depression in order to provide an update on the state of this field for clinicians and researchers. The review focuses on the HPA axis-based interventions of corticotropin-releasing factor antagonists and the glucocorticoid receptor antagonist mifepristone, the HPT axis-based treatments of thyroid hormones (T3 and T4), and the HPG axis-based treatments of estrogen replacement therapy, the progesterone derivative allopregnanolone, and testosterone. While some treatments have largely failed to translate from preclinical studies, others have shown promising initial results and represent active fields of study in the search for novel effective treatments for major depression.
引用
- Dwyer JB, Aftab A, Radhakrishnan R, et al. Hormonal Treatments for Major Depressive Disorder: State of the Art. Am J Psychiatry. 2020. PMID: 32456504. doi:10.1176/appi.ajp.2020.19080848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。